Cyclopharm Hits 381 US Sites as Hospital Networks Race to Add Technegas Systems
Cyclopharm reaches inflection point as US Technegas rollout accelerates
Cyclopharm Limited (ASX: CYC) has declared it is operating at an inflection point in its Cyclopharm USA Technegas Expansion, as the radiopharmaceutical company builds on multi-site agreements announced last week with expansion of existing contracts and new institutional wins. The 31 March 2026 update signals a strategic shift from early-stage market entry to scaled institutional penetration across US healthcare networks.
The company now operates 50 revenue-generating installations linked to an additional 331 contracted locations. Cyclopharm has engaged with approximately one quarter of the 5,139 US sites performing nuclear medicine lung imaging, demonstrating significant market penetration in a sector historically dominated by alternative diagnostic modalities.
This announcement signals Cyclopharm is transitioning from proving market viability to demonstrating repeatable, scalable growth. For commercial-stage medtech companies, this transition represents a critical inflection where institutional adoption patterns validate the product-market fit and create visibility on future revenue trajectories.
When big ASX news breaks, our subscribers know first
Major health systems deepen Technegas adoption
Expansion within existing institutional networks
Cyclopharm is leveraging existing institutional relationships to drive network expansion, with recent wins demonstrating a functioning “land and expand” strategy where initial lighthouse sites catalyse system-wide adoption.
Mass General Brigham installed a second system at Brigham and Women’s Hospital on 31 March 2026, following the successful Massachusetts General Hospital deployment in 2025. Brigham and Women’s represents the sixth Top 20 hospital in the US to implement Technegas, reinforcing the product’s credibility within elite academic medical centres.
Additional expansion within existing networks includes:
- University of North Carolina Health System: First system installed, with a second scheduled within days
- Emory Health Care: Fourth system ordered, demonstrating utilisation growth across their network
- Joseph Maxwell Cleland Atlanta VA Medical Center: Purchase order received, installation expected mid-April; represents the fifth VA hospital to adopt Technegas
Multi-site adoption within existing networks de-risks growth forecasts. These installations represent proven relationships expanding rather than cold leads requiring extended sales cycles. For investors, this pattern provides greater confidence in near-term revenue conversion and validates the replicability of Cyclopharm’s commercial model.
New institutional agreements secured
Two new health system contracts strengthen Cyclopharm’s geographic footprint in strategically important markets. Both agreements target leading academic medical centres, reinforcing the company’s strategy of securing high-credibility institutional anchors.
The Medical University of South Carolina (MUSC) contract includes an initial two-site installation with potential for three additional affiliated locations. MUSC represents Cyclopharm’s first installation in South Carolina, expanding the company’s presence into a new state market.
Stony Brook University Health System signed a contract with purchase order received for two Technegas systems. Located in Long Island, New York, Stony Brook serves as the primary tertiary care provider for the region. This installation deepens Cyclopharm’s penetration in the New York market, a strategic priority given the concentration of high-volume nuclear medicine facilities in metropolitan areas.
New state entry combined with deeper penetration in established markets demonstrates Cyclopharm’s ability to execute on both geographic expansion and market density strategies simultaneously.
Understanding the US medtech expansion model
Cyclopharm’s US commercialisation follows a three-stage expansion strategy common to successful medtech rollouts, designed to build credibility before pursuing scale.
Lighthouse sites represent initial installations at prestigious hospitals that validate the technology and create reference points for other institutions. These early adopters provide clinical data, workflow integration insights, and peer-to-peer advocacy that accelerates subsequent sales cycles.
Regional density focuses on building clusters of installations in key metropolitan markets. This approach creates efficient sales and service infrastructure while establishing local clinical champions who influence adoption decisions at neighbouring facilities.
Network expansion leverages relationships within integrated healthcare systems to drive multi-site adoption from a single entry point. Once Technegas demonstrates clinical utility and operational efficiency at one facility, expansion across the broader system faces reduced procurement friction.
Cyclopharm is now demonstrating progression from Stage 1 to Stages 2 and 3 simultaneously. The company has established credibility through lighthouse sites while building regional density and capturing network expansion opportunities. This staged approach mirrors successful medtech commercialisation playbooks, with validation preceding scale.
Contract pipeline signals sustained growth runway
Cyclopharm’s contract pipeline provides visibility across multiple time horizons, with opportunities spanning immediate revenue generation through to early-stage proposal activity.
| Pipeline Stage | Primary Sites | Secondary Locations | Total Opportunity |
|---|---|---|---|
| Revenue generating | 50 | 331 | 381 |
| Contracting/installation | 74 | 103 | 177 |
| Active contract review | 48 | 49 | 97 |
| Internal committee review | 96 | 90 | 186 |
| Proposal/conversion stage | 643 | 69+ | 712+ |
The distinction between primary installations and secondary locations reflects the network effect inherent in integrated healthcare systems. A single primary installation can catalyse adoption across multiple affiliated facilities, amplifying the commercial impact of individual wins.
Cyclopharm has engaged with approximately 25% of the total addressable market of 5,139 US nuclear medicine lung imaging sites. This engagement rate, combined with the layered pipeline structure, provides visibility on both near-term revenue conversion and longer-term growth potential as opportunities progress through procurement stages.
Clinical guideline inclusion expected to accelerate adoption
Technegas has been included in the draft US and international clinical guideline for ventilation-perfusion (V/Q) imaging, where it is recognised as a preferred ventilation imaging agent. The guideline, developed by leading global nuclear medicine bodies, is expected to be finalised at the upcoming SNMMI annual meeting in late May 2026.
Clinical guidelines represent the highest level of clinical evidence and play a critical role in shaping physician practice, hospital procurement and reimbursement decisions.
Guideline endorsement removes a key barrier to adoption. Physicians can reference authoritative clinical consensus when advocating for Technegas procurement within their institutions, reducing the internal friction that often delays capital equipment approvals in hospital settings.
For investors, guideline inclusion represents a potential catalyst for accelerated uptake. Formal clinical recognition validates the product’s clinical utility and positions Technegas as a standard of care rather than an optional alternative. This shift in clinical positioning can meaningfully compress sales cycles and expand addressable market penetration.
Strategic channels support scalable deployment
Government contracts represent a strategic priority for Cyclopharm, providing both credibility and scalable deployment pathways. The fifth VA hospital has adopted Technegas through the Joseph Maxwell Cleland Atlanta VA Medical Center purchase order, with installation expected mid-April.
Additional Veterans Affairs and military hospitals continue to progress through approval and procurement processes. Government healthcare systems operate standardised procurement frameworks, creating potential for coordinated multi-site deployments once initial validation is achieved.
Federal healthcare validation carries significant commercial weight. VA and military hospital adoption signals to private sector institutions that Technegas meets rigorous clinical and operational standards, reducing perceived adoption risk for subsequent prospects.
The next major ASX story will hit our subscribers first
What this means for Cyclopharm’s investment case
Key investment implications from the 31 March 2026 update include:
- Inflection point declared by management, signalling confidence in commercial momentum and the transition from market entry to scaled penetration
- Land-and-expand strategy validated through multi-site institutional adoption within Mass General Brigham, UNC Health, Emory Health Care and the VA system
- Pipeline depth provides revenue visibility across immediate (contracting/installation), near-term (contract review) and longer-term (proposal stage) time horizons
- Guideline inclusion expected in May 2026 creates potential catalyst for accelerated uptake as Technegas achieves formal clinical standard-of-care recognition
- Government channel progression adds credibility through federal validation and creates standardised procurement pathways for coordinated multi-site deployment
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements drop across biotech, medtech and pharmaceutical sectors.